Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2026-01-05 00:00:00 ET · period of report 2025-12-31 · accession 0001213900-26-001279 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-01-05 | 2025-12-31 | ORMP | Kidron Miriam | CSO, Dir | A - Grant | $0.00 | +236.3K | 1.43M | +20% | $0 |
| D | 2026-01-05 | 2025-12-31 | ORMP | Kidron Miriam | CSO, Dir | A - Grant | $0.00 | +19.0K | 19.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-31 | A | A | 121,331 | $0.00 | 1,314,664 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. |
| 2 | Common | Common Stock | 2025-12-31 | A | A | 115,000 | $0.00 | 1,429,664 | D | — | — | (F2) Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer. |
| 3 | Derivative | Performance Stock Units | 2025-12-31 | A | A | 19,000 | $0.00 | 19,000 | D | — · — to — | 19,000 Common Stock | (F3) Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria. |